This table is provided for informational purposes only. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantees concerning reimbursement or coverage for any service or item.
Please visit CMS.gov or other payers’ websites to obtain additional guidance on their processes related to billing and coding for single-use vials and wastage.
|174.0 – 174.9||Malignant neoplasm of female breast|
|175.0, 175.9||Malignant neoplasm of male breast|
|Drug: HCPCS†||J9306||Injection, pertuzumab, 1 mg|
|50242-145-01||50242-0145-01||420 mg/14 mL single-use vial|
|Select Services, Procedures and Supplies: CPT®||||96413||Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug|
|96415||Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)|
|96417||Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)|
|*||International Classification of Diseases, 9th Revision, Clinical Modification.|
|†||Healthcare Common Procedure Coding System.|
|‡||National Drug Code.|
|§||Payer requirements regarding use of a 10-digit or 11-digit NDC may vary. Both formats are listed here for your reference. PERJETA Access Solutions provides this information when we perform a benefits investigation (BI) for your patient.|
|||||Current Procedural Terminology.|
If your office has prescribed PERJETA, but your patient’s insurer has denied coverage, you can appeal that decision. PERJETA Access Solutions might be able to help you as you resolve the situation. Here is what you can do*:
Tips and Checklists